Olympus Europa and Applied Spectral Imaging Expand Cooperation by Establishing Sales and Marketing Framework Agreement
The agreement further outlines Olympus Europa’s and Applied Spectral Imaging’s commitment and intent to cooperate in the distribution of state-of-the-art pathology and cytogenetic microscopy imaging solutions in Europe
Hamburg, Germany and Carlsbad, Calif., May 29, 2012 – OLYMPUS Europa Holding GmbH and Applied Spectral Imaging (ASI) Ltd. today signed a European framework agreement outlining the terms for distribution by Olympus subsidiaries in Europe of the GenASIs automated imaging platforms for genetic and pathological analysis. This agreement underlines both companies’ intent to establish cooperation with individual Olympus distributors in Europe. These agreements will be based on the Framework Agreement to deliver integrated computer aided microscopy imaging and analysis for cytogenetics and pathology.
The GenASIs advanced cytogenetic and pathology platforms are the foundation of ASI’s offering. With its superior imaging and analysis capabilities, ASI provides state-of-the-art diagnostic aids, offering cytogeneticists and pathologists accurate biomedical analysis.
GenASIs enables automated pathology tissue analysis for primary diagnostics, creating reproducible and reliable results. The GenASIs platforms offer a comprehensive solution ensuring reliability and quality results every time, while allowing cytogeneticists, pathologists and technologists to focus on the clinical rather than the technical components.
GenASIs is FDA cleared for FISH clinical applications such as UroVysion, HER2/neu, CEP XY and Karyotyping.
ASI’s advanced solutions integrated with Olympus’ microscopy solutions accommodate the market demand for faster, more powerful imaging and analysis tools. This unparalleled synergy caters to the growing market need for high throughput solutions empowering laboratories to do more with less.
GenASIs will complement Olympus’ solutions by offering an integrated imaging, digital image capture and biomedical analysis platform.
“We are excited about our cooperation with Olympus. Cooperating with the world’s leader in microscopy will further enhance ASI’s position as the leaders in computer aided biomedical microscopy imaging and analysis” said Limor Shiposh, CEO of Applied Spectral Imaging.
With this co-operation agreement both companies show their commitment of working together in order to offer more competitive integrated solutions and to facilitate the daily work in medical applications.
About OLYMPUS Europa Holding GmbH
Since Olympus was founded in Japan in 1919, it has become a leading manufacturer of innovative optical and digital equipment for the healthcare and consumer electronics sectors. For over 90 years it has led the way in designing endoscopy and microscopy equipment for both medical and industrial use, and it is well known for its groundbreaking camera and voice recorder ranges.
The Olympus Europe Group posted a turnover of EUR 1,386 million in the financial year 2011-2012. Its European head office is located in Hamburg, Germany. The Olympus Europe Group employs some 4,700 people either at the European headquarters or at one of the 44 subsidiary companies.
About Applied Spectral Imaging
Applied Spectral Imaging (ASI) makes patient care better through advanced biomedical imaging.
GenASIs by ASI is FDA cleared for FISH clinical applications such as UroVysion, HER2/neu, CEP XY and Karyotyping. ASI complies with major regulatory requirements and international quality standards.
ASI has been one of the industry's leading microscopy imaging solution provider since 1993, with over 30 registered patents in the US, Europe and Japan and over 2,500 systems deployed worldwide. With worldwide offices in the US, Europe and Asia, ASI has built a global network of over 50 distributors.
# # #
For More Information Contact –
Applied Spectral Imaging
Limor Shiposh, Chief Executive Officer
Tel: +1(800) 611-3466
On behalf of OLYMPUS EUROPA HOLDING GMBH
Paul Avery (PR Account Manager)
Tel: +44 (0) 1489 557 672
Fax: +44 (0) 1489 559 246